Allianz advisor and economist Mohamed El-Erian stated that he concurs with the general perception that the Fed is confused and divided about its long-term outlook.
Stocktwits·41m ago
Will Nifty Test New Highs? SEBI Analysts See Key Resistance At 25,400–25,650
With global cues supportive, analysts see limited hurdles for Nifty until the 25,650–25,700 zone, while downside support remains strong near 25,250.
Stocktwits·49m ago
Why Did Bullish Stock Rise Over 2% After-Hours Today?
Peter Thiel-backed Bullish also reported a net income of $108.3 million for the second quarter, compared with a net loss of $116.4 million in the year-ago quarter.
Stocktwits·1h ago
Trump Cheers ABC For Axing Jimmy Kimmel’s Show Over Charlie Kirk Remarks, Critics Warn Of Political Crackdown
Kimmel had said that the "MAGA gang" was trying to score political points off Kirk's murder.
Stocktwits·2h ago
Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up
The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity.
Stocktwits·2h ago
Uber CEO Renews Robotaxi Pitch To Tesla CEO Elon Musk: ‘We’re Your Ticket to Maximizing That Revenue’
The pitch underscores Uber’s bid to stay central in the robotaxi race as it partners with Tesla on freight and faces fresh competition from Lyft’s new Waymo alliance in Nashville.
Stocktwits·2h ago
Meta Stock Inches Up After-Hours As Zuckerberg Unveils $799 AI Glasses: Analyst Calls It ‘Best Bang For The Buck’
The company said the new Meta Ray-Ban Display glasses are the first product to integrate microphones, speakers, cameras, and a full-color display, backed by compute and AI, all in a single device that is both stylish and comfortable.
Stocktwits·2h ago
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said.